Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3-treated myelin peptide-loaded tolerogenic dendritic cells in progressive multiple sclerosis
2025-522040-40-01Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Apr 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of myelin peptide-loaded tolerogenic dendritic cells in multiple sclerosis (MS), sponsored by Antwerp University Hospital. Primary endpoints: Change in Expanded Disability Status Scale (EDSS) score and Safety and tolerability of tolDC. Planned start Apr 2026; status: authorised.
02
Drugs
myelin peptide-loaded tolerogenic dendritic cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-522040-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522040-40-01.